Despite the clinical efficacy of B-RAFV600/MEK targeted inhibitors, a large subset of melanoma patients develop resistance due to the reactivation of other elements of the MAPK or the PI3K pathway and receptor tyrosine kinases (e.g., c-KIT) [8,9,10,11]. The gene discussed is MAP2K7; the disease is melanoma.